Salarius Pharmaceuticals, Inc. - SLRX STOCK NEWS

Salarius Pharmaceuticals (Nasdaq: SLRX) announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company focuses on developing innovative cancer therapies, particularly its lead candidate, seclidemstat, which is in clinical trials for pediatric cancers and advanced solid tumors. Salarius has received multiple designations from the FDA for seclidemstat and financial support from the National Pediatric Cancer Foundation and CPRIT to further its clinical programs.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that Dr. Daniela Y. Santiesteban will join the panel on Targeted Cancer Therapeutics at Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference, taking place January 19-21, 2021, virtually. The discussion will focus on the status and future of targeted cancer therapies. Salarius is advancing its lead candidate, seclidemstat, a reversible LSD1 inhibitor, currently undergoing clinical trials for Ewing sarcoma and advanced solid tumors. The company aims to establish maximum tolerated dose in its ongoing trials.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced a $0.9 million payment from the Cancer Prevention and Research Institute of Texas, part of a $1.7 million grant for its lead drug candidate, seclidemstat. This funding supports two clinical trials targeting Ewing sarcoma and advanced solid tumors. With a total of $4.8 million in remaining funds, Salarius is positioned to advance its clinical programs. The company has secured additional funding of $3.6 million from prior financing efforts, allowing it to progress through critical development milestones in 2021.

Salarius Pharmaceuticals is set to participate in the Biotech Showcase Digital and BIO @ JPM from January 11-15, 2021. This virtual participation coincides with the 39th Annual Healthcare Conference 2021. Salarius aims to discuss its clinical programs for seclidemstat, a potential treatment for Ewing sarcoma and other cancers. Key milestones include establishing maximum tolerated doses and advancing into the dose-expansion phase of trials. Salarius has received FDA designations for its lead candidate, focusing on pediatric and solid tumors.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced agreements with institutional investors to exercise outstanding warrants, raising approximately $3.5 million by issuing 3,964,065 shares. This follows their public offering in February 2020. The exercised warrants' price was reduced from $1.15 to $0.90 to encourage immediate cash exercise. New warrants will allow the purchase of additional shares at $1.182, exercisable in six months. The funds will support the development of seclidemstat, focusing on pediatric and solid tumors, with key milestones expected in early 2021.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced a $0.8 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT), part of a total expected of $1.7 million. This funding supports the development of seclidemstat, its lead drug candidate, being evaluated in clinical trials for Ewing sarcoma and advanced solid tumors. Salarius aims to achieve several milestones, including determining the maximum tolerated dose in the Ewing sarcoma trial and expanding the study to include related sarcomas. Total CPRIT disbursements will reach $11.3 million with this funding.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced CEO David Arthur's participation in A.G.P.’s Virtual Healthcare Symposium on November 19, 2020. The focus will be on their lead drug candidate, seclidemstat, an oral medication targeting lysine-specific demethylase 1 (LSD1), crucial in some cancers. Ongoing Phase 1/2 trials for seclidemstat involve patients with refractory Ewing sarcoma and advanced solid tumors. Notably, one patient showed over 80% reduction in target lesions after six months of treatment.

Salarius Pharmaceuticals (Nasdaq: SLRX) reported its Q3 2020 financial results, revealing a net loss of $1.7 million, or $0.10 per share, significantly reduced from a loss of $2.6 million or $0.73 per share year-over-year. The company’s cash position improved to $9.6 million, aided by a $6.2 million public offering in August 2020. The Ewing sarcoma clinical trial is progressing, with plans to enter the Phase 2 dose-expansion stage in Q1 2021 and an expansion to include Ewing-related sarcomas. Salarius aims to leverage these developments for future growth.

Salarius Pharmaceuticals (SLRX) announced a conference call on November 11, 2020, at 4:30 p.m. ET to discuss its third-quarter 2020 corporate and financial results. Investors can join the call by dialing (833) 423-0481 or (918) 922-2375 with Conference ID 1277839. An audio webcast will also be available on the company's website. Salarius focuses on developing cancer therapies, including its lead candidate, seclidemstat, which is in clinical trials for pediatric and other cancers and has received multiple designations from the FDA.